PDCD1 and neoplasm: The anti-PD-1 pembrolizumab has been approved by the FDA for the treatment of patients with TMB-high (TMB ≥ 10 Mutations/Megabase) independent of tumor origin, based on biomarker analysis from the KEYNOTE-158 trial.